Comment: Use of recalibrated serum creatinine concentrations for adjustment of drug dosages: Determination of values compatible with conventional dosing recommendations

Annals of Pharmacotherapy

Volumn 45, Issue 12, 2011, Pages 1592-1593

  Palacio Lacambra, M Eugenia ^a   Jiménez Lozano, Inés ^a   Vidal Otero, Jana ^a   Montoro Ronsano, José Bruno ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GANCICLOVIR;

CALIBRATION; CHRONIC KIDNEY DISEASE; CORRELATION COEFFICIENT; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FOOD AND DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; HUMAN; ISOTOPE DILUTION MASS SPECTROMETRY; KIDNEY FUNCTION; LETTER; MASS SPECTROMETRY; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRIORITY JOURNAL;

CREATININE; HUMANS; KIDNEY FAILURE, CHRONIC; PHARMACEUTICAL PREPARATIONS;

EID: 83155189763     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P676a     Document Type: Letter

References (9)

1. Jones MA, Golightly LK, Stolpman NM. Use of recalibrated serum creatinine concentrations for adjustment of drug dosages: determination of values compatible with conventional dosing recommendations. Ann Pharmacother 2011;45:748-56. DOI 10.1345/aph.1P676
2. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12. 3.
3. Levey AS, Coresh J, Greene T, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007;53:766-72. DOI 10.1373/clinchem.2006.077180
4. Levey AS, Stevens LA. Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis 2010;55:622-7. DOI 10.1053/j.ajkd.2010.02.337
5. Palacio ME, Jiménez I, Vidal J, Montoro B. Evaluation of the predictive ability of different renal function estimation formulas on the estimation of elimination kinetics of ganciclovir. Presented at: 46th ASHP Midyear Clinical Meeting & Exhibition, New Orleans, LA, December 4-8, 2011.
6. Food and Drug Administration. Draft guidance for industry: pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labeling. US Department of Health and Human Services, 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM204959.pdf (accessed 2011 Aug 5).
7. Food and Drug Administration. Guidance for industry: pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labeling. US Department of Health and Human Services, May 1998. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072127.pdf (accessed 2011 Aug 5).
8. European Medicines Agency. Note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function. Committee for Medical Products for Human Use, June 2004. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003123.pdf (accessed 2011 Aug 5).
9. National Kidney Disease Education Program. Chronic kidney disease and drug dosing: information for providers. Revised January 2010. http://nkdep.nih.gov/professionals/drug-dosing-information.htm (accessed 2011 Aug 5).